R229
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 97
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.360
- PROTEIN_SECRETION+0.310
- WNT_BETA_CATENIN_SIGNALING+0.230
- UV_RESPONSE_DN+0.130
- OXIDATIVE_PHOSPHORYLATION+0.080
- APOPTOSIS+0.070
- PI3K_AKT_MTOR_SIGNALING+0.060
- HEME_METABOLISM+0.040
- P53_PATHWAY+0.040
- MYC_TARGETS_V1+0.020
Top 10 suppressed
- E2F_TARGETS-0.560
- G2M_CHECKPOINT-0.410
- ALLOGRAFT_REJECTION-0.380
- IL6_JAK_STAT3_SIGNALING-0.370
- INTERFERON_ALPHA_RESPONSE-0.350
- INFLAMMATORY_RESPONSE-0.340
- INTERFERON_GAMMA_RESPONSE-0.340
- CHOLESTEROL_HOMEOSTASIS-0.280
- PANCREAS_BETA_CELLS-0.280
- APICAL_SURFACE-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202454 | — | — | 0.832 |
| 2 | SRR8942980 | — | — | 0.819 |
| 3 | SRR25043615 | — | — | 0.809 |
| 4 | SRR1516088 | — | — | 0.806 |
| 5 | DRR168549 | — | — | 0.795 |
| 6 | SRR1516046 | — | — | 0.793 |
| 7 | SRR1516060 | — | — | 0.790 |
| 8 | SRR1516042 | — | — | 0.781 |
| 9 | GSM5359426 | — | — | 0.781 |
| 10 | TCGA-78-7167-01A-11R-2066-07 | — | cohortA2 | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.080 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.040 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.020 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |